IKT
Inhibikase Therapeutics, Inc.Company with tickers: IKT
CIK
1750149
CUSIP
45719W205
Shares Outstanding
132,032,636
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $0 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $10,513,579 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-14,598,006 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-13,678,735 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.15 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.15 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |